# Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Source: https://onco.cc/trials/nct04782687/  
OnCo record `nct04782687` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Selinexor, Daratumumab, Lenalidomide in multiple myeloma, run by US Oncology Research, active and no longer recruiting.

## Summary

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma is a phase 2 interventional study registered as NCT04782687 by US Oncology Research, with 73 participants enrolled, started 2021-09-10 and due to reach its primary completion in 2026-05-31. Interventions recorded: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide. Conditions listed: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04782687
- Phase: 2
- Setting: A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
- Sponsor: US Oncology Research
- Enrolled: 73

## Sources

- ClinicalTrials.gov NCT04782687: https://clinicaltrials.gov/study/NCT04782687

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Daratumumab](https://onco.cc/drugs/daratumumab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [McKesson / The US Oncology Network](https://onco.cc/companies/mckesson-us-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct04782687.json